INDOLENT T-CELL
LYMPHOPROLIFERATIVE DISORDER OF THE GI TRACT
Post-transplant
lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival.
The proapoptotic protein Bax is also expressed at high levels in CD30+ cutaneous lymphoproliferative diseases and may play a crucial role in mediating apoptosis of tumor cells.9 The CD30+ cutaneous
lymphoproliferative disorders account for approximately 25% of cutaneous T-cell lymphoma cases.10 Black persons may be less affected by lymphomatoid papulosis than persons of other racial groups.
CD30+ cutaneous
lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Meloni, "Post-transplant
lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients," Virology Journal, vol.
The reported clinical case is about a patient who developed CMV/EBV ventriculoencephalitis that, despite the virological response to antiviral therapy with ganciclovir and foscarnet, evolved to EBV-driven B cell
lymphoproliferative disorder that is considered a "grey disorder" (neither benign nor malignant) that usually evolves to PCNSL [4].
Posttransplant
lymphoproliferative disorder (PTLD) is a very grave complication of immunosuppression in transplant patients.
Cytological diagnoses were 10
lymphoproliferative disorders, 95 adenocarcinomas, 55 squamous cell carcinoma, 25 neuroendocrine tumours, 29 metastasis from other neoplasms, 14 poorly differentiated nonsmall-cell lung cancer, and 13 other malignancies (2 mixed adenocarcinomas and neuroendocrine, 2 adenoid cystic carcinomas, 1 pleomorphic carcinoma, 1 sarcomatoid carcinoma, 1 nonspecific CTM, 3 epithelioid mesotheliomas, 1 poorly differentiated epithelioid neoplasm, 1 mesenchymal neuron neoplasm, and 1 sarcoma).
Kempf, "CD30+
lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators," Journal of Cutaneous Pathology, vol.
Boyiadzis, "Primary central nervous system post-transplant
lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation," Journal of Neuro-Oncology, vol.
It has morphologic and immunophenotypic characteristics that distinguish it from the other HHV8
lymphoproliferative disorders.
